



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

ReACp53 acetate


Chemical Properties

CAS No. :

Formula: C110H210N52O26

Molecular Weight: 2677.18

Appearance: no data available

Storage: store at low temperature, keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Biological Description

Description	ReACp53 acetate could inhibit p53 amyloid formation and rescue p53 function in cancer cell lines.
Targets(IC50)	p53
In vitro	ReACp53 acetate penetrates into HGSOC primary cancer cells and converts mutant p53 from a punctate state into soluble WT-like p53. ReACp53 acetate also induces cancer cell death, cell cycle arrest and results in p53 degradation. ReACp53 acetate specifically affects cell viability and proliferation of cancer cells bearing mutant p53 but not wild type when grown as organoids[1].
In vivo	Only mutant p53-bearing tumors in the ReACp53 acetate-treated mice cohorts are 80-90% smaller in weight than the control cohort, confirming the ability of ReACp53 acetate to limit tumor proliferation and shrink tumors. A significant reduction of Ki67 positive cells is evident in ReACp53 acetate-treated OVCAR3 xenografts, indicative of a reduced proliferative index. Similar results are observed in the minimal residual disease model. In the paradigm, administration of ReACp53 acetate results in a significant increase in p21 and MDM2 transcription in OVCAR3 but not MCF7 xenografts. A significantly increased population is also found in G0/G1 phase, supporting proliferative arrest upon ReACp53 acetate administration in vivo[1].

Solubility Information

Solubility	H2O: 9 mg/mL (3.4 mM) (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	0.3735 mL	1.8676 mL	3.7353 mL
5 mM	0.0747 mL	0.3735 mL	0.7471 mL
10 mM	0.0374 mL	0.1868 mL	0.3735 mL
50 mM	0.0075 mL	0.0374 mL	0.0747 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Soragni A et al. A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas. Cancer Cell. 2016 Jan 11;29(1):90-103.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481